HLB Pharma Announces 32.8% Rights Offering with Undisclosed Use of Proceeds

On May 13, 2026, HLB Pharma decided to issue 10,762,332 common shares (32.81% of outstanding) via rights offering. Record date: July 1, 2026.
Existing shareholders receive 0.3281321329 shares per share. Issue price to be determined with discount of 25-40%. Lead underwriter: Korea Investment & Securities (60%), co-lead: Hana Securities (30%), Hanyang Securities (10%).
The purpose of the capital raise (facilities, operations, debt repayment, etc.) was not disclosed. Investors should note the uncertainty regarding use of funds.
Subscription schedule: Existing shareholders: Aug 10-11; public offering: Aug 13-14. Rights certificates expected to be listed from July 24 to July 30.